Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.01). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX traded down $0.10 during mid-day trading on Tuesday, hitting $2.04. The company’s stock had a trading volume of 2,952 shares, compared to its average volume of 413,328. The business’s fifty day moving average is $2.23 and its two-hundred day moving average is $3.44. The stock has a market cap of $87.95 million, a price-to-earnings ratio of -0.60 and a beta of 2.17. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $17.55.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KYTX. HC Wainwright lowered their price target on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, April 3rd. Morgan Stanley lowered their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Kyverna Therapeutics has a consensus rating of “Buy” and an average target price of $18.33.

Hedge Funds Weigh In On Kyverna Therapeutics

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE grew its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,788 shares of the company’s stock after purchasing an additional 6,400 shares during the period. Bank of America Corp DE owned approximately 0.05% of Kyverna Therapeutics worth $81,000 as of its most recent filing with the Securities & Exchange Commission. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.